Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Aug 28;8(8):1008-1009.
doi: 10.1016/j.jacbts.2023.05.001. eCollection 2023 Aug.

INKing the Cardiotoxicity Out of Doxorubicin

Zhen Guo  1 , Ali Javaheri  1   2
Affiliations
Editorial

INKing the Cardiotoxicity Out of Doxorubicin

Zhen Guo et al. JACC Basic Transl Sci. .
No abstract available

Keywords: cardiomyopathy; doxorubicin; inflammatory; interferon-gamma; invariant natural killer T cells.

PubMed Disclaimer

Conflict of interest statement

Dr Javaheri was supported by 1R01HL155344 from the National Heart, Lung, and Blood Institute and by the Children’s Discovery Institute of Washington University and St. Louis Children's Hospital (MC-FR-2020-919); supported by the Diabetes Research Center at Washington University in St. Louis of the National Institutes of Health under award number P30DK020579; supported by National Institutes of Health grant P30DK056341 (Nutrition Obesity Research Center); has a pending patent for fusion protein nanodiscs for the treatment of heart failure and eye disease, is a member of the scientific advisory board of Mobius Scientific, and has received research funding from AstraZeneca and Bitterroot Bio, unrelated to the studies in this paper. Dr Guo was supported by the American Heart Association Postdoctoral Fellowship (898679).

Figures

None
Graphical abstract
See this image and copyright information in PMC

Comment on

  • doi: 10.1016/j.jacbts.2023.02.014

References

    1. Rawat P.S., Jaiswal A., Khurana A., Bhatti J.S., Navik U. Doxorubicin-induced cardiotoxicity: an update on the molecular mechanism and novel therapeutic strategies for effective management. Biomed Pharmacother. 2021;139 - PubMed
    1. Obata Y., Ishimori N., Saito A., et al. Activation of invariant natural killer T cells by alpha-galactosylceramide ameliorates doxorubicin-induced cardiotoxicity in mice. Eur J Prev Cardiol. 2020;27:2358–2361. - PubMed
    1. Sada M., Matsushima S., Ikeda M., et al. IFN-γ-STAT1-ERK pathway mediates protective effects of invariant natural killer T cells against doxorubicin-induced cardiomyocyte death. J Am Coll Cardiol Basic Trans Science. 2023;8:992–1007. - PMC - PubMed
    1. Guo Z., Valenzuela Ripoll C., Picataggi A., et al. Apolipoprotein M attenuates anthracycline cardiotoxicity and lysosomal injury. J Am Coll Cardiol Basic Trans Science. 2023;8:340–355. - PMC - PubMed
    1. Ozcan M., Guo Z., Valenzuela Ripoll C., et al. Sustained alternate-day fasting potentiates doxorubicin cardiotoxicity. Cell Metab. 2023;S1550-4131(23):00042–00046. - PMC - PubMed

Publication types

LinkOut - more resources